Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group | Zendy

R.M. Rudd | Zendy; N.H. Gower | Zendy; Stephen Spiro | Zendy; Tim Eisen | Zendy; Peter Harper | Zendy; J.A.H. Littler | Zendy; M. Hatton | Zendy; Peter Johnson | Zendy; William McChesney Martin | Zendy; Elaine M. Rankin | Zendy; L. E. James | Zendy; W. Gregory | Zendy; W. Qian | Zendy; SM Lee | Zendy

Open Access

Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group

Author(s) -

R.M. Rudd,

N.H. Gower,

Stephen Spiro,

Tim Eisen,

Peter Harper,

J.A.H. Littler,

M. Hatton,

Peter Johnson,

William McChesney Martin,

Elaine M. Rankin,

L. E. James,

W. Gregory,

W. Qian,

SM Lee

Publication year - 2004

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.03.037

Subject(s) - medicine , carboplatin , ifosfamide , gemcitabine , lung cancer , chemotherapy , hazard ratio , gastroenterology , cisplatin , surgery , oncology , urology , confidence interval

This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC). The regimens were compared with regard to effects on survival, response rates, toxicity, and quality of life.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research